RNF5 Expression Profiling in Neuroblastoma and Melanoma

Publicly available datasets found on the R2: Genomic Analysis and Visualization http://r2.amc.nl platform (accessed on 1 October 2021) were used for the evaluation of RNF5 expression in NB primary tumor and melanoma samples. The NB dataset (GSE49710) contains the expression profiles of 498 NB specimens (211 female and 287 male patients, with a diagnosis age ranging from 0 to 25 years; the 75% of patients received the diagnosis before 3 years of age) measured with the Illumina HiSeq 2000 RNAseq platform [16 (link)] whereas the melanoma dataset (GSE65904) reports the gene expression profiles of 214 melanoma tumor samples analyzed with Illumina Human HT-12V4.0 BeadChip arrays [17 (link)]. RNF5 differential expression and survival analyses were performed with R2 platform tools, using the median value as a cut-off to define high or low gene expression. The differential expression of RNF5 between high-risk and low-risk NB patients was reported as Log₂ fold change (FC) value and the significance was calculated with ANOVA test. Patient overall survival (OS) and event-free survival (EFS) were assessed by Kaplan-Meier curves. The separation significance of the survival curves was assessed with log-rank test adjusted by the Bonferroni method.